BRUSELLS – The European Union will meet AstraZeneca executives on Monday to seek further clarification on why they unexpectedly announced a large cut in supplies of COVID-19 vaccine to the bloc for the first quarter of the year, EU officials said.
AstraZeneca, which developed its shot with Oxford University, told the EU on Friday that it could not meet the agreed supply targets running up to the end of March, with an EU official telling Reuters that meant a 60% cut to 31 million doses.
The Anglo-Swedish drugmaker has received an up-front payment of 336 million euros ($409 million) from the EU, a second EU official told Reuters when the 27-nation bloc sealed a supply deal with AstraZeneca in August for at least 300 million doses — the first signed by the EU to secure COVID-19 shots.
Under advance purchase deals sealed during the pandemic, the EU makes down payments to companies to secure doses, with the money expected to be mostly used to expand production capacity. “Initial volumes will be lower than originally anticipated due to reduced yields at a manufacturing site within our European supply chain,” AstraZeneca said on Friday. The site in question is a vaccine factory in Belgium run by the drugmaker’s partner Novasep.
The EU Commission said a meeting was called with AstraZeneca after Friday’s announcement, and is due to start in the early afternoon on Monday. AstraZeneca was not immediately available to comment on Monday.
The first EU official, who has been directly involved in talks with AstraZeneca, said there were no high expectations about the meeting in which the company will be asked to better explain the delays, although its outcome is still unclear. The official declined to be named due to the confidential nature of the discussions.
Earlier in January, Pfizer, which is currently the largest supplier of COVID-19 vaccines to the EU, announced delays of nearly a month to its shipments, but hours later revised this to say the delays would last only a week.
EU contracts with vaccine makers are confidential, but the EU official did not rule out possible penalties for AstraZeneca, given the large revision to its earlier commitments. However, the source did not elaborate on what could trigger the penalties. “We are not there yet,” the official added.
AstraZeneca’s vaccine is expected to be approved for use in the EU on Jan. 29, with first deliveries expected from Feb. 15.